Alopecia Secondary to Endocrine Therapy in Postmenopausal Women With Breast Cancer
- Conditions
- Breast Cancer
- Registration Number
- NCT01300871
- Lead Sponsor
- University Health Network, Toronto
- Brief Summary
This is a study to determine the prevalence and severity of alopecia (hair loss) experienced by postmenopausal breast cancer patients receiving endocrine therapy including Tamoxifen, Letrozole (Femara), Exemestane (Aromasin), or Anastrozole (Arimidex).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- Female
- Target Recruitment
- 100
- Postmenopausal women
- Diagnosed with hormone-receptor positive breast cancer
- Commenced adjuvant endocrine therapy ≥ 3 months ago, specifically Tamoxifen, Anastrozole, Exemestane, and/or Letrozole
- Good command of the English language
- Under the care of a medical oncologist at Princess Margaret Hospital
- Previously received chemotherapy
- Recurrent and/or metastatic disease
- History of endocrine, dermatology, or immune system disorders known to alter hair growth (ie. Hypothyroidism and iron deficiency)
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Severity of Alopecia Tool (SALT) 1 year The proportion of postmenopausal breast cancer patients on endocrine therapy who experience grade S1 to S5 alopecia as defined by the Severity of Alopecia Tool (SALT).
- Secondary Outcome Measures
Name Time Method Severity of Alopecia Tool (SALT) 1 year To identify the severity, or grade, of hair loss experienced by our target population. The severity of alopecia will be represented as a percentage, again in accordance with the SALT.
Comparison of Tamoxifen, AI or Tamoxifen plus AI 1 year Comparison of the proportion of postmenopausal breast cancer patients treated with Tamoxifen monotherapy, AI monotherapy, or a switch from Tamoxifen to AI who experience alopecia.
Trial Locations
- Locations (1)
Princess Margaret Hospital
🇨🇦Toronto, Ontario, Canada